产品名称

TMI 005 - Apratastat

产品货号

Axon 1507 CAS [287405-51-0] MF C17H22N2O6S2MW 414.50 Purity: 99% Optical purity: >98% ee Soluble in DMSO Description Novel, oral TACE/MMP inhibitor for rheumatoid arthritis; Apratastat (TMI-005) blocks secretion of soluble TNF-α and down regulates multiple MMPs, which have been implicated in cartilage destruction and bone erosions of RA References Certificates Categories Extra info MM Thabet and TWJ Huizinga. Apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr. Opin. Investig. Drugs. 2006, 7(11), 1014-1019. ML Moss et al. Drug Insight: Tumor Necrosis Factor Converting Enzyme as a Pharmaceutical Target for Rheumatoid Arthritis. Nat. Clin. Pract. Rheumatol. 2008, 4(6), 300. C Shu et al. Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach. J. Clin. Pharmacol. 2011, 51(4), 472-481. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Signaling & Oncology Immunology Miscellaneous Pain & Inflammation TACE NF-κB EC 3.4.24.86 TACE/MMP inhibitor Chemical name (S)-4-[4-(4-Hydroxy-but-2-ynyloxy)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide Parent CAS No. [287405-51-0] Order Size Unit Price Stock 5 mg €125.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

TMI 005 - Apratastat

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 1507

CAS [287405-51-0]

MF C17H22N2O6S2
MW 414.50

Purity: 99%
Optical purity: >98% ee
Soluble in DMSO

TMI 005

Description

Novel, oral TACE/MMP inhibitor for rheumatoid arthritis; Apratastat (TMI-005) blocks secretion of soluble TNF-α and down regulates multiple MMPs, which have been implicated in cartilage destruction and bone erosions of RA